The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform ...
Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible ...
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the first patient ...
San Diego biotech Neomorph, which is developing a protein degradation-based platform to enable novel drug development for hard-to-treat diseases, has raised $109 million in a Series A round of venture ...
Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph that could be worth up to ...
Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. AbbVie will pay ...
Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results